Jordan Stanford, Anita Stefoska-Needham, Xiaotao Jiang, Brett McWhinney, Hicham I Cheikh Hassan, Emad El-Omar, Karen Charlton, Kelly Lambert
{"title":"High-Diversity Plant-Based Diet and Gut Microbiome, Plasma Metabolome, and Symptoms in Adults with CKD.","authors":"Jordan Stanford, Anita Stefoska-Needham, Xiaotao Jiang, Brett McWhinney, Hicham I Cheikh Hassan, Emad El-Omar, Karen Charlton, Kelly Lambert","doi":"10.2215/CJN.0000000682","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Research suggests that eating a plant-dominant dietary pattern is beneficial to people with chronic kidney disease (CKD). The aim was to investigate how increasing the diversity of plant food intake would impact metabolomic, microbiome and clinical parameters in people with CKD.</p><p><strong>Methods: </strong>This study was a cross-over, randomized controlled trial involving 25 Australian adults diagnosed with stage 3-4 CKD. Participants were randomly allocated to follow two diets for 6 weeks each, separated by a minimum 4-week washout period: a high-diversity plant-based diet (HDPD, ≥30 unique plant foods weekly) and a low-diversity plant-based diet (LDPD, ≤15 unique plant foods weekly), alongside a usual kidney diet prescription. Data collection was completed at four timepoints (beginning and end of each intervention period). Primary outcome included a change in uremic toxins (indoxyl sulfate and p-Cresyl sulfate) concentrations. Secondary and exploratory outcomes included diet quality and nutritional status, fecal microbiome composition and diversity, plasma metabolome, symptom burden, quality of life scores, blood pressure, biochemical and anthropometric measures.</p><p><strong>Results: </strong>Plasma and urinary uremic toxin levels did not consistently decrease across the cohort; however, significant reductions were observed in responders to the HDPD, particularly those with poorer kidney function and higher baseline uremic toxin levels. Neither diet caused electrolyte imbalances. The HDPD significantly improved diet quality, reduced potential renal acid load by an average of 47% from baseline, with an estimated marginal mean reduction of 9.96 (95% CI: -16.28 to -3.64), and compared to the LDPD, decreased total symptom burden, including constipation (95% CI: -4.11 to -0.54 and -0.91 to -0.22, respectively). It also shifted the gut microbiome toward increased production of beneficial metabolites like butyrate/isobutyrate. In contrast, the LDPD reduced microbial diversity and decreased the abundance of 27 species and 33 functional genes.</p><p><strong>Conclusions: </strong>This study demonstrated the safety and clinically relevant therapeutic benefits of aiming to incorporate 30 or more unique plant foods weekly in the diet of individuals with moderate CKD. It was observed that individuals with more advanced kidney disease and higher levels of uremic toxins may derive the greatest benefit from adopting a HDPD.</p><p><strong>Trial registration: </strong>ACTRN12619000442101.</p>","PeriodicalId":50681,"journal":{"name":"Clinical Journal of the American Society of Nephrology","volume":" ","pages":""},"PeriodicalIF":8.5000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Journal of the American Society of Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2215/CJN.0000000682","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Research suggests that eating a plant-dominant dietary pattern is beneficial to people with chronic kidney disease (CKD). The aim was to investigate how increasing the diversity of plant food intake would impact metabolomic, microbiome and clinical parameters in people with CKD.
Methods: This study was a cross-over, randomized controlled trial involving 25 Australian adults diagnosed with stage 3-4 CKD. Participants were randomly allocated to follow two diets for 6 weeks each, separated by a minimum 4-week washout period: a high-diversity plant-based diet (HDPD, ≥30 unique plant foods weekly) and a low-diversity plant-based diet (LDPD, ≤15 unique plant foods weekly), alongside a usual kidney diet prescription. Data collection was completed at four timepoints (beginning and end of each intervention period). Primary outcome included a change in uremic toxins (indoxyl sulfate and p-Cresyl sulfate) concentrations. Secondary and exploratory outcomes included diet quality and nutritional status, fecal microbiome composition and diversity, plasma metabolome, symptom burden, quality of life scores, blood pressure, biochemical and anthropometric measures.
Results: Plasma and urinary uremic toxin levels did not consistently decrease across the cohort; however, significant reductions were observed in responders to the HDPD, particularly those with poorer kidney function and higher baseline uremic toxin levels. Neither diet caused electrolyte imbalances. The HDPD significantly improved diet quality, reduced potential renal acid load by an average of 47% from baseline, with an estimated marginal mean reduction of 9.96 (95% CI: -16.28 to -3.64), and compared to the LDPD, decreased total symptom burden, including constipation (95% CI: -4.11 to -0.54 and -0.91 to -0.22, respectively). It also shifted the gut microbiome toward increased production of beneficial metabolites like butyrate/isobutyrate. In contrast, the LDPD reduced microbial diversity and decreased the abundance of 27 species and 33 functional genes.
Conclusions: This study demonstrated the safety and clinically relevant therapeutic benefits of aiming to incorporate 30 or more unique plant foods weekly in the diet of individuals with moderate CKD. It was observed that individuals with more advanced kidney disease and higher levels of uremic toxins may derive the greatest benefit from adopting a HDPD.
期刊介绍:
The Clinical Journal of the American Society of Nephrology strives to establish itself as the foremost authority in communicating and influencing advances in clinical nephrology by (1) swiftly and effectively disseminating pivotal developments in clinical and translational research in nephrology, encompassing innovations in research methods and care delivery; (2) providing context for these advances in relation to future research directions and patient care; and (3) becoming a key voice on issues with potential implications for the clinical practice of nephrology, particularly within the United States. Original manuscript topics cover a range of areas, including Acid/Base and Electrolyte Disorders, Acute Kidney Injury and ICU Nephrology, Chronic Kidney Disease, Clinical Nephrology, Cystic Kidney Disease, Diabetes and the Kidney, Genetics, Geriatric and Palliative Nephrology, Glomerular and Tubulointerstitial Diseases, Hypertension, Maintenance Dialysis, Mineral Metabolism, Nephrolithiasis, and Transplantation.